Doctors in Britain who treated former Russian spy Sergei Skripal and his daughter following their March poisoning in Salisbury have said they initially feared the pair would not recover.
Skripal and his daughter Yulia, who was visiting from Moscow, collapsed on March 4 on a bench in the city in southwestern England where the former double agent lived.
London blamed Moscow for using a Soviet-made nerve agent known as novichok on the pair, which Moscow has furiously denied, sparking a diplomatic crisis between Russia and Britain.
Stephen Jukes, the intensive care consultant at Salisbury District Hospital, who treated them a week after their admission, said in a BBC interview that once the nerve agent was detected "all the evidence was there that they would not survive".
Jukes revealed the hospital's medical team first suspected the Skripals were suffering from an opioid overdose, but that the diagnosis soon changed to a nerve agent poisoning.
The doctors interviewed said that all the initial focus was on simply keeping the pair alive. The pair were heavily sedated and given large doses of drugs designed to protect them from the effects of the poison and help re-start their bodies' natural production of a key enzyme.
When a third person involved, police officer Nick Bailey, was admitted with similar symptoms, medical staff said they feared the situation could be escalating out of control.
"There was a real concern as to how big could this get," said Lorna Wilkinson, the director of nursing.
She added that she recalled thinking: "have we just gone from having two index patients [to] having something that actually could become all-consuming and involve many casualties?' because we really didn't know at that point."
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
